Nifty Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news and updates on Nifty Pharma from all sources in a single place.

Load latest

Alkem Laboratories Ltd.

10 Mar 2025

4700.50

-2.65%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

This is to inform you that Mr. Shirish Purushotham Ambulgekar has been appointed at the senior management position of the Company w.e.f. 10th March, 2025.

pdf

Sun Pharmaceutical Industries Ltd.

10 Mar 2025

1666.35

-2.52%

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355 million; shares edge higher

livemint

Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the FDA-approved drug UNLOXCYT. The deal, expected to close in 2025, reflects Sun Pharma's strategy to strengthen its oncology presence and improve patient access to innovative treatments.

Sun Pharmaceutical Industries Ltd.'s price crossed below 50Day SMA today

Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn

Business Standard | 10 Mar 2025 3 more

Gland Pharma Ltd.

10 Mar 2025

1415.80

-4.00%

Company Update

Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Appointment of Mr. Wriddhee Maitra as Vice - President (Human Resources) of the Company with effect from March 10, 2025

pdf

Alkem Laboratories Ltd.

10 Mar 2025

4700.50

-2.65%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please find enclosed herewith the details of investor meetings scheduled to be held on 17th March, 2025, 18th March, 2025, 19th March, 2025, 24th March, 2025 and 25th March, 2025.

pdf

Zydus Lifesciences Ltd.

10 Mar 2025

837.60

-3.38%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zydus receives final approval from USFDA for Ketoconazole Shampoo, 2%.

pdf

Glenmark Pharmaceuticals Ltd.

10 Mar 2025

1442.20

-3.84%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Glenmark Therapeutics Inc., Polyethylene Glycol 3350

pdf

Sun Pharmaceutical Industries Ltd.

10 Mar 2025

1666.35

-2.52%

Company Update

Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Acquisition of Checkpoint Therapeutics

pdf

Sun Pharmaceutical Industries Ltd.

10 Mar 2025

1666.35

-2.52%

Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio

Buy: Sun Pharmaceutical Industr...

BOB Capital Markets Ltd.

SUNP to acquire Checkpoint Therapeutic for US$ 4.10 a share, at ~66% premium to its last closing price. Deal valued at US$ 355mn

Sun Pharmaceutical Industries Ltd.'s price crossed below 30Day SMA today

Granules India Ltd.

09 Mar 2025

436.90

-4.35%

USFDA flags Granules India for storage, equipment lapses at Telangana plant

Business Standard

The US health regulator has pulled up Granules India for failing to maintain buildings for drug storage and avoiding adequate procedures regarding cleaning and maintenance of equipment at its Telangana-based formulations plant. In a warning letter to the company's Chairman and Managing Director Krishna Prasad Chigurupati, the US Food and Drug Administration (USFDA) stated that the company failed to establish and follow adequate written procedures for maintaining equipment at the Medchal-Malkajgiri-based manufacturing facility. The USFDA inspected the facility from August 26 to September 6, 2024. "Our investigators observed significant contamination in multiple ducts of non-dedicated use in the preparation of finished drug products manufactured at your facility," the USFDA stated. While filters were installed to prevent contamination, inadequate cleaning and maintenance processes rendered them ineffective, it added. "Swab samples collected from the ducts by your firm during the...